Showing 1 - 2 results of 2 for search 'Timothy B London', query time: 0.03s Refine Results
  1. 1
    1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19

    1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19 by Agapitos Patakas, Naveen K Mehta, Patrick A Baeuerle, Jennifer S Michaelson, Kristan A Meetze, Hannah M Findlay, Timothy B London

    Published 2023-11-01
    Article
  2. 2
    CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression

    CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression by Agapitos Patakas, Bochong Li, Naveen K Mehta, Kristan Meetze, Patrick A Baeuerle, Jennifer S Michaelson, Hannah M Findlay, Timothy B London

    Published 2023-08-01
    Get full text
    Article

Search Tools: